Abstract:4 Objectives Monoacylglycerol lipase (MAGL) is a 33 kDa member of the serine hydrolase superfamily that preferentially degrades 2-arachidonoylglycerol (2-AG) to arachidonic acid in the endocannabinoid system. Inhibition of MAGL is not only of interest for probing the cannabinoid pathway but also as therapeutic and diagnostic target for neuroinflammation. Since only limited attempts have been made to image MAGL in vivo, the search for a suitable PET ligand for this target is urgently sought. Herein we developed two 11C-labeled MAGL inhibitors based on a novel sulfonamide core and performed preliminary PET studies in rodents. Methods A library of twenty sulfonamido carbamates / ureas with a series of alterations in terminal aryl moieties, linkers and leaving groups was synthesized and evaluated in a MAGL / fatty acid amide hydrolase (FAAH)/ cannabinoid receptors (CB1/CB2) competitive binding assay, an artificial membrane permeability assay and a hydrolysis stability assay. The most promising compounds, namely N-((1-(1H-1,2,4-triazole-1-carbonyl)piperidin-4-yl)methyl)-4-chlorobenzenesulfonamide (TZPU), and 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(((4-chlorophenyl)sulfonamido)methyl)piperidine-1-carboxylate (SAR127303), were radiolabeled at the 11C-carbonyl position via [11C]COCl2. Dynamic PET imaging studies in Sprague-Dawley rats were carried out under anesthesia in a Siemens Inveon scanner for 90 min. Results Two equipotent and selective MAGL inhibitors, TZPU and SAR127303 (ca. 50% MAGL inhibition @ 50 nM; no FAAH inhibition, CB1 and CB2 receptors antagonism @ 10 µM; good permeability >2.0 x 10-6 cm/s) were selected for further radiotracer development. [11C]TZPU and [11C]SAR127303 were radiolabeled in 3.1% and 35% uncorrected yields, relative to 11CO2, respectively, with specific activities >2 Ci/µmol and radiochemical purities >99%. PET imaging of [11C]TZPU in rats showed a limited brain uptake (0.4 SUV) and no significant washout during the scan. Pretreatment with TZPU (1 mg/kg, 30 min i.v. before injection) resulted in a 50% reduction in the accumulation of radioactivity in the brain, indicating certain specificity of [11C]TZPU. [11C]SAR127303 demonstrated high whole brain uptake (2 SUV peaked at 3 min) and no significant clearance during the scan. The distribution was heterogeneous with the highest radioactivity in the cerebellar cortex and striatum, followed by hippocampus, cerebellum and the lowest in pons, which is consistent with MAGL distribution in the rat brain. Pretreatment studies with SAR127303 (1 mg/kg, 30 min i.v. before injection) remarkably decreased the brain uptake (75% reduction) and abolished the difference of uptakes in brain regions. Blocking studies with a potent FAAH inhibitor, URB597 (3 mg/kg, 30 min i.v. before injection), showed no effect towards the uptake and distribution in rat brains as predicted for this selective MAGL radiotracer. Conclusions [11C]SAR127303 shows promise as a proof-of-concept radiotracer for neuroimaging of MAGL. PET studies in nonhuman primates are underway and will be presented in due course.

Structure-Activity Relationship Studies of Aryl Sulfoxides as Reversible Monoacylglycerol Lipase Inhibitors

A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence

Design, synthesis and biological evaluation of naphthyl amide derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors

Structure-Guided Discovery of cis -Hexahydro-pyrido-oxazinones as Reversible, Drug-like Monoacylglycerol Lipase Inhibitors

Discovering monoacylglycerol lipase inhibitors by a combination of fluorogenic substrate assay and activity-based protein profiling

Discovery of Potent and Reversible Monoacylglycerol Lipase Inhibitors.

Development of Potent and Selective Monoacylglycerol Lipase Inhibitors. SARs, Structural Analysis, and Biological Characterization

Discovery of Novel Reversible Monoacylglycerol Lipase Inhibitors Via Docking-Based Virtual Screening.

Novel Reversible-Binding PET Ligands for Imaging Monoacylglycerol Lipase Based on the Piperazinyl Azetidine Scaffold

A potent and selective inhibitor for the modulation of MAGL activity in the neurovasculature

Design, Synthesis, and Evaluation of Reversible and Irreversible Monoacylglycerol Lipase Positron Emission Tomography (PET) Tracers Using a “tail Switching” Strategy on a Piperazinyl Azetidine Skeleton

Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders

Discovery of Aryl Formyl Piperidine Derivatives As Potent, Reversible, and Selective Monoacylglycerol Lipase Inhibitors.

Highly Selective Inhibitors of Monoacylglycerol Lipase Bearing a Reactive Group that Is Bioisosteric with Endocannabinoid Substrates

A Novel Class of Sulfonamido [C-11-Carbonyl]-labeled Carbamates and Ureas as Radiotracers for Monoacylglycerol Lipase

Discovery of a Novel Class of Reversible Monoacylglycerol Lipase Inhibitors for Potential Treatment of Depression.

Structure Optimization of 12β-O-γ-Glutamyl Oleanolic Acid Derivatives Resulting in Potent FXR Antagonist/Modulator for NASH Therapy

Protein Degradation via CRL4 CRBN Ubiquitin Ligase: Discovery and Structure-Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of Aiolos and/or GSPT1.

Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.

Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling

Elucidating the Binding Mechanism of LPA Species and Analogs in an LPA4 Receptor Homology Model